There are no formal guidelines to help direct antipsychotic selection for delirium in pediatric patients. A 2020 literature review evaluated 42 studies to assess the use of antipsychotics (haloperidol, quetiapine, olanzapine, and risperidone) for the treatment of delirium in pediatric patients in the intensive care unit (ICU). All four agents have shown similar efficacy in managing pediatric delirium; however, there are no standardized dosing or delirium evaluation protocols/tools during most published literature. Overall the selection of antipsychotic agent should be based on patient-specific factors that include risk of QT prolongation, oral intake status, weight, and age. [1], [2]
Pediatric delirium is typically underdiagnosed due to complications of evaluating nonverbal/preverbal children, meaning the diagnosis is mostly based on behavioral symptoms. Four delirium rating scales have been developed and validated in an attempt to increase awareness of pediatric delirium: The Pediatric Anesthesia Emergence Delirium Scale, the Pediatric Confusion Assessment Method for the ICU, the Cornell Assessment of Pediatric Delirium, and the Sophia Observation Withdrawal Symptoms-Pediatric Delirium Scale. All four tools have similar sensitivities (83%-94%), specificities (79%-98%), and ease of use. Thus, there is no clear best tool to use for evaluating pediatric delirium. [1], [2]
Haloperidol has been reported in intravenous (IV) doses ranging from 0.003 to 0.278 mg/kg/dose for about three to 22 days. Although haloperidol was efficacious for the treatment of pediatric delirium, this medication was associated with dystonia and other unacceptable side effects that occurred in about 14.5% of the patient population. The authors of this review and case reports suggest these side effects outweigh the potential benefit from haloperidol use. [1], [2]
Quetiapine use has been reported in 82 infants and older children. These studies revealed that quetiapine has a good safety profile for this population with only about 3.7% of patients experiencing QT prolongation, with no progression to torsade de pointes. Quetiapine dosing was weight-based ranging from 0.43 to 2.8 mg/kg/q8h. Studied quetiapine duration for pediatric delirium ranged from nine days to two months. [1], [2]
Olanzapine has been studied in at least 78 children with delirium. No weight-based dose or dose frequency was found for olanzapine in this review. Studies utilized doses ranging from 0.625/day to 10 mg/day; however, some studies reported higher doses of up to 60 mg of olanzapine per day. Although some studies reported efficacy and safety, there was no documentation of time to symptom improvement, nor was there mention of a taper to discontinuation. [1], [2]
Risperidone has been studied in at least 34 pediatric patients for delirium. Of these 34 patients, zero experienced adverse drug events. The daily risperidone dose ranged from 0.1 to 2 mg/kg/day and the duration of therapy ranged from one to 151 days. Of the four studies included for risperidone, one of the four documented the time to symptom improvement: all the patients in this study had improvement within 24 hours; delirium resolved within 3.5 to 12 days. [1], [2]